1. Home
  2. NBTX

NBTX

Nanobiotix S.A.

Logo Nanobiotix S.A.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Founded: 2003 Country:
France
France
Employees: N/A City: N/A
Market Cap: 291.1M IPO Year: 2020
Target Price: $11.00 AVG Volume (30 days): 20.8K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.79 EPS Growth: N/A
52 Week Low/High: $1.75 - $11.00 Next Earning Date: 04-26-2024
Revenue: $7,406,593 Revenue Growth: 182.84%
Revenue Growth (this year): 615.45% Revenue Growth (next year): 69.55%

Share on Social Networks: